ERBB2 and breast cancer: It is well known that triple-negative breast cancer, with the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-type 2 (HER2), is a highly aggressive mammary tumor subtype, responsible for about 12–20% of all breast cancer cases.